NYSE:NNVC

NanoViricides (NNVC) Stock Forecast, Price & News

$1.44

+0.04 (+2.86%)

(As of 09/27/2023 ET)

Compare

Today's Range: $1.37
▼
$1.46
50-Day Range: $1.25
▼
$1.70
52-Week Range: $1.04
▼
$2.00

Volume: 29,686 shs
Average Volume: 59,118 shs
Market Capitalization: $16.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

About NanoViricides (NYSE:NNVC) Stock

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.

NNVC Price History

30 days | 90 days | 365 days | Advanced Chart

NNVC Stock News Headlines

September 20, 2023 | americanbankingnews.com

NanoViricides (NYSE:NNVC) Now Covered by StockNews.com

September 5, 2023 | finance.yahoo.com

NNVC: NanoViricides Begins Clinical Trial of NV-CoV-2

September 27, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 31, 2023 | finance.yahoo.com

NanoViricides progressing well with new Covid study

August 29, 2023 | msn.com

$NNVC Reports Their Broad-Spectrum Antiviral Drugs Human Clinical Trial Is Progressing Successfully

August 23, 2023 | proactiveinvestors.com

NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses

August 21, 2023 | finance.yahoo.com

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

July 18, 2023 | benzinga.com

SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?

September 27, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

July 13, 2023 | finance.yahoo.com

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

July 11, 2023 | marketwatch.com

NanoViricides Shares Surge on NV-387 Showing in RSV >NNVC

July 11, 2023 | benzinga.com

Why Are NanoViricides Shares Gaining Today

July 11, 2023 | finance.yahoo.com

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides

July 10, 2023 | benzinga.com

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

July 8, 2023 | proactiveinvestors.com

NanoViricides says clinical trial progressing satisfactorily...NanoViricides says clinical trial progressing satisfactorily for...

July 6, 2023 | finance.yahoo.com

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

June 29, 2023 | finance.yahoo.com

NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2

June 29, 2023 | proactiveinvestors.com

NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2

June 29, 2023 | finanznachrichten.de

NanoViricides, Inc.: NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

June 29, 2023 | finance.yahoo.com

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

May 31, 2023 | finance.yahoo.com

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

May 19, 2023 | proactiveinvestors.com

Big box retailers lead mixed earnings week as consumers shift focus from goods to experiences

May 16, 2023 | proactiveinvestors.com

NanoViricides ends fiscal 3Q with strong cash runway to begin clinical trials of broad-spectrum COVID drug

May 16, 2023 | finanznachrichten.de

NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

May 16, 2023 | finance.yahoo.com

NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

May 4, 2023 | finance.yahoo.com

NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City

April 25, 2023 | finance.yahoo.com

NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient

See More Headlines

Receive NNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter.

NNVC Company Calendar

Last Earnings: 11/15/2021
Today: 9/27/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NNVC
CUSIP: N/A
CIK: 1379006
Web: www.nanoviricides.com
Phone: (203) 937-6137
Fax: 203-859-5095
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.25
High Stock Price Forecast: $5.25
Low Stock Price Forecast: $5.25
Forecasted Upside/Downside: +269.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,110,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.87%
Return on Assets: -32.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 28.46
Quick Ratio: 28.46

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.00 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 11,640,000
Free Float: 11,123,000
Market Cap: $16.53 million
Optionable: Optionable
Beta: 1.17

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Anil R. Diwan Ph.D. (Age 64)
Exec. Chairman, Pres, CEO & Sec.
Comp: $400k

Ms. Meeta R. Vyas B.S. (Age 64)
M.B.A., SB, MBA, Chief Financial Officer
Comp: $129.6k

Dr. Randall W. Barton Ph.D. (Age 76)
Chief Scientific Officer & Chief Regulatory Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NNVC Stock - Frequently Asked Questions

Should I buy or sell NanoViricides stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NNVC shares.
View NNVC analyst ratings or view top-rated stocks.
What is NanoViricides' stock price forecast for 2023?: 1 Wall Street analysts have issued 12-month target prices for NanoViricides' shares. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they anticipate the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 269.7% from the stock's current price.
View analysts price targets for NNVC or view top-rated stocks among Wall Street analysts.
How have NNVC shares performed in 2023?: NanoViricides' stock was trading at $1.11 on January 1st, 2023. Since then, NNVC shares have increased by 27.9% and is now trading at $1.42.
View the best growth stocks for 2023 here.
How were NanoViricides' earnings last quarter?: NanoViricides, Inc. (NYSE:NNVC) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.03.
When did NanoViricides' stock split?: NanoViricides shares reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is NanoViricides' stock symbol?: NanoViricides trades on the New York Stock Exchange (NYSE) under the ticker symbol "NNVC."
Who are NanoViricides' major shareholders?: NanoViricides' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.68%), Two Sigma Securities LLC (0.21%) and Citadel Advisors LLC (0.00%).
View institutional ownership trends.
How do I buy shares of NanoViricides?: Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NanoViricides' stock price today?: One share of NNVC stock can currently be purchased for approximately $1.42.
How much money does NanoViricides make?: NanoViricides (NYSE:NNVC) has a market capitalization of $16.53 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.
How can I contact NanoViricides?: NanoViricides' mailing address is 1 Controls Drive, Shelton CT, 06484. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at clyburn@tradigitalir.com, or via fax at 203-859-5095.

This page (NYSE:NNVC) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial